Uridine Diphosphate Glucose (UDP-G) Activates Oxidative Stress and Respiratory Burst in Isolated Neutrophils.

NADPH oxidase P2Y14-R PMN UDP-glucose free radicals neutrophils oxidative stress respiratory burst

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
21 Oct 2023
Historique:
received: 14 09 2023
revised: 17 10 2023
accepted: 18 10 2023
medline: 28 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

The extracellular purinergic agonist uridine diphosphate glucose (UDP-G) activates chemotaxis of human neutrophils (PMN) and the recruitment of PMN at the lung level, via P2Y14 purinergic receptor signaling. This effect is similar to the activation of PMN with N-formyl-methionyl-leucyl-phenylalanine (fMLP), a mechanism that also triggers the production of superoxide anion and hydrogen peroxide via the NADPH oxidase system. However, the effects of UDP-G on this system have not been studied. Defects in the intracellular phagocyte respiratory burst (RB) cause recurrent infections, immunodeficiency, and chronic and severe diseases in affected patients, often with sepsis and hypoxia. The extracellular activation of PMN by UDP-G could affect the RB and oxidative stress (OS) in situations of inflammation, infection and/or sepsis. The association of PMNs activation by UDP-G with OS and RB was studied. OS was evaluated by measuring spontaneous chemiluminescence (CL) of PMNs with a scintillation photon counter, and RB by measuring oxygen consumption with an oxygen Clark electrode at 37 °C, in non-stimulated cells and after activation (15 min) with lipopolysaccharides (LPS, 2 µg/mL), phorbol myristate acetate (PMA, 20 ng/mL), or UDP-G (100 μM). The stimulation index (SI) was calculated in order to establish the activation effect of the three agonists. After stimulation with LPS or PMA, the activated PMNs (0.1 × 10

Identifiants

pubmed: 37895972
pii: ph16101501
doi: 10.3390/ph16101501
pmc: PMC10609875
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Vet Pathol. 2010 Sep;47(5):881-92
pubmed: 20664013
Mol Pharmacol. 2015 Jul;88(1):151-60
pubmed: 25829059
Stem Cell Rev Rep. 2021 Feb;17(1):241-252
pubmed: 33575962
Br J Pharmacol. 1970 Dec;40(4):668-88
pubmed: 4322041
Am J Respir Cell Mol Biol. 2005 Dec;33(6):601-9
pubmed: 16109883
J Allergy Clin Immunol. 2015 Oct;136(4):838-47
pubmed: 26277597
Acta Physiol (Oxf). 2010 Jun;199(2):149-60
pubmed: 20345417
Brain Res Mol Brain Res. 2003 Oct 21;118(1-2):10-23
pubmed: 14559350
Nat Rev Immunol. 2013 May;13(5):349-61
pubmed: 23618831
Mol Pharmacol. 2013 Jul;84(1):41-9
pubmed: 23592514
Br J Pharmacol. 2006 Jan;147 Suppl 1:S172-81
pubmed: 16402102
Genes Dev. 2003 Jul 1;17(13):1592-604
pubmed: 12842911
Curr Opin Pharmacol. 2009 Jun;9(3):262-7
pubmed: 19285919
Purinergic Signal. 2012 Sep;8(3):359-73
pubmed: 22528679
Trends Microbiol. 2017 Jun;25(6):456-466
pubmed: 28089288
Annu Rev Biochem. 2017 Jun 20;86:715-748
pubmed: 28441057
J Physiol. 2007 Oct 1;584(Pt 1):245-59
pubmed: 17656429
Antioxid Redox Signal. 2001 Jun;3(3):505-13
pubmed: 11491661
Trends Immunol. 2007 Aug;28(8):340-5
pubmed: 17627888
Pharmacol Rev. 2006 Sep;58(3):281-341
pubmed: 16968944
Physiol Rev. 1979 Jul;59(3):527-605
pubmed: 37532
Am J Physiol Cell Physiol. 2012 Sep 1;303(5):C490-8
pubmed: 22673622
FEBS Lett. 1994 Mar 14;341(1):65-8
pubmed: 8137924
Front Cell Infect Microbiol. 2017 Aug 25;7:373
pubmed: 28890882
EMBO Rep. 2019 May;20(5):
pubmed: 30872317
Purinergic Signal. 2016 Dec;12(4):627-635
pubmed: 27421735
Curr Protoc Immunol. 2001 May;Chapter 7:7.23.1-7.23.17
pubmed: 18432834
Am J Respir Cell Mol Biol. 2011 Aug;45(2):253-60
pubmed: 20935191
Mod Pathol. 2020 Jun;33(6):1007-1014
pubmed: 32291399
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Infect Immun. 1982 Jan;35(1):350-5
pubmed: 7054126

Auteurs

Fabiana Lairion (F)

Cátedra de Química General e Inorgánica, Departamento de Ciencias Químicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113AAD, Argentina.
Instituto de Bioquímica y Medicina Molecular Prof. Alberto Boveris, Consejo Nacional de Investigaciones Científicas y Tecnológicas (IBIMOL, UBA-CONICET), Buenos Aires 1113AAD, Argentina.

Claudio Carbia (C)

Cátedra de Bioquímica Clínica II-Área Hematología, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires 1113AAD, Argentina.

Iris Maribel Chiesa (IM)

Cátedra de Química General e Inorgánica, Departamento de Ciencias Químicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113AAD, Argentina.

Christian Saporito-Magriña (C)

Cátedra de Química General e Inorgánica, Departamento de Ciencias Químicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113AAD, Argentina.
Instituto de Bioquímica y Medicina Molecular Prof. Alberto Boveris, Consejo Nacional de Investigaciones Científicas y Tecnológicas (IBIMOL, UBA-CONICET), Buenos Aires 1113AAD, Argentina.

Natalia Borda (N)

Cátedra de Bioquímica Clínica II-Área Hematología, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires 1113AAD, Argentina.

Alberto Lazarowski (A)

Cátedra de Bioquímica Clínica II-Área Hematología, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires 1113AAD, Argentina.

Marisa Gabriela Repetto (MG)

Cátedra de Química General e Inorgánica, Departamento de Ciencias Químicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113AAD, Argentina.
Instituto de Bioquímica y Medicina Molecular Prof. Alberto Boveris, Consejo Nacional de Investigaciones Científicas y Tecnológicas (IBIMOL, UBA-CONICET), Buenos Aires 1113AAD, Argentina.

Classifications MeSH